文献速递白血病造血干细胞移植与细胞治疗

替沙基奥仑赛在婴儿急性淋巴细胞白血病中的真实世界应用

Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2022-01-01

该回顾性研究基于儿童真实世界CAR联盟数据,评估2017至2020年间14例接受替沙基奥仑赛治疗的婴儿B细胞急性淋巴细胞白血病患者。64%(9例)达微小残留病阴性缓解,末次随访时50%仍缓解;输注时高疾病负荷(>M1骨髓)者均难治。总体可耐受,仅3例发生≥3级细胞因子释放综合征,无神经毒性报告。

要点

  • 14例婴儿B-ALL患者接受替沙基奥仑赛,64%(9例)达MRD阴性缓解,50%末次随访仍缓解。
  • 输注时高疾病负荷(>M1骨髓)者均对该治疗难治(n=5)。
  • 总体可耐受,仅3例发生≥3级细胞因子释放综合征,无神经毒性报告。

核心结论

  • 替沙基奥仑赛在婴儿B-ALL中安全且可能有效,是该人群最大宗的替沙基奥仑赛使用报告。

研究设计与样本

  • 回顾性评估儿童真实世界CAR联盟(Pediatric Real-World CAR Consortium)数据,纳入2017至2020年间接受替沙基奥仑赛的婴儿B-ALL患者14例。

主要发现

  • 64%患者(n=9)在CAR-T后达微小残留病阴性缓解,50%患者在末次随访时仍处于缓解。
  • 输注时高疾病负荷(>M1骨髓)的所有患者均对该治疗难治(n=5)。
  • 总体替沙基奥仑赛在该人群可耐受,仅3例患者发生≥3级细胞因子释放综合征。
  • 未报告神经毒性。

临床怎么用

  • 作者认为将这一新型免疫治疗纳入婴儿B-ALL的治疗,为一种高度侵袭性白血病提供了有前景的疗法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infants with B-cell acute lymphoblastic leukemia (B-ALL) have poor outcomes because of chemotherapy resistance leading to high relapse rates. Tisagenlecleucel, a CD19-directed chimeric antigen receptor T-cell (CART) therapy, is US Food and Drug Administration approved for relapsed or refractory B-ALL in patients ≤25 years; however, the safety and efficacy of this therapy in young patients is largely unknown because children <3 years of age were excluded from licensing studies. We retrospectively evaluated data from the Pediatric Real-World CAR Consortium to examine outcomes of patients with infant B-ALL who received tisagenlecleucel between 2017 and 2020 (n = 14). Sixty-four percent of patients (n = 9) achieved minimal residual disease-negative remission after CART and 50% of patients remain in remission at last follow-up. All patients with high disease burden at time of CART infusion (>M1 marrow) were refractory to this therapy (n = 5). Overall, tisagenlecleucel was tolerable in this population, with only 3 patients experiencing ≥grade 3 cytokine release syndrome. No neurotoxicity was reported. This is the largest report of tisagenlecleucel use in infant B-ALL and shows that this therapy is safe and can be effective in this population. Incorporating this novel immunotherapy into the treatment of infant B-ALL offers a promising therapy for a highly aggressive leukemia.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Moskop A, Pommert L, Baggott C, et al. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Adv. 2022. PMID: 35580324. doi:10.1182/bloodadvances.2021006393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。